Glioblastoma multiforme (GBM) is the most frequent and deadly type of primary malignant tumor in the central nervous system with a median survival range of only 9-15 months. We developed and validated a MRI-based radiomics classifier to predict overall survival(OS) in patients with newly diagnosed GBM. The results showed that a 7-radiomics classifier allows prediction of survival and stratification of patients with newly diagnosed GBM into a low- or high-risk group for OS.
This abstract and the presentation materials are available to members only; a login is required.